David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky; Chief ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Archie and Olivia Manning’s tight-knit family is often referred to as the first family of American football. Now, there is ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly posted a 45% jump in revenue to $13.53 billion, driven by the success of its diabetes and weight-loss treatments. Adjusted profit also beat expectations, coming in at $5.32 per share versus ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...

Eli Lilly ripped off the bandage when it reported preliminary fourth-quarter results in mid-January, getting the bad news out ...

The timing fit. Remember, President Trump signed an executive order on his first day of his second stint in the Oval Office that the federal government define a person's sex as either male or female.

Investing.com - Eli Lilly's full-year profit forecast largely surpassed Wall Street expectations on Thursday, as the ...